CEBPD and uterine corpus leiomyoma: Co-localization of CEBPD and T lymphocyte marker CD3E was confirmed in clinical specimens.<h4>Conclusion</h4><i>CEBPD</i> emerges as a potential prognostic biomarker for uterine fibroids.